Resistance to neoadjuvant chemotherapy in triple-negative breast cancer mediated by a reversible drug-tolerant state
Gloria V. Echeverria(Baylor College of Medicine), Helen Piwnica‐Worms(Centre for Cancer Biology), Jeffrey T. Chang(Tufts University), Michael Peoples(The University of Texas MD Anderson Cancer Center), Zhongqi Ge(The University of Texas MD Anderson Cancer Center), Christopher A. Bristow(The University of Texas MD Anderson Cancer Center), Mariano J. Alvarez(Columbia University Irving Medical Center), Xinhui Zhou(Zhejiang University), Shirong Cai(Sun Yat-sen University), Yuting Sun(The University of Texas MD Anderson Cancer Center), Sabrina L. Jeter-Jones(The University of Texas MD Anderson Cancer Center), Prabhjot S. Mundi(Columbia University Irving Medical Center), Andrea Califano(Johns Hopkins University), Joseph R. Marszalek(The University of Texas MD Anderson Cancer Center), Alessandro Carugo(The University of Texas MD Anderson Cancer Center), Timothy P. Heffernan(The University of Texas MD Anderson Cancer Center), Vandhana Ramamoorthy(The University of Texas MD Anderson Cancer Center), Qing Chang(Beijing University of Chinese Medicine), Rosanna Lau(The University of Texas MD Anderson Cancer Center), Xiaomei Zhang(The University of Texas MD Anderson Cancer Center), Yun Wu(The University of Texas MD Anderson Cancer Center), Angela L. Harris(The University of Texas MD Anderson Cancer Center), Xiaoyan Ma(Shanghai East Hospital), Stacy Moulder(The University of Texas MD Anderson Cancer Center), Jiansu Shao(The University of Texas MD Anderson Cancer Center), Huan Qiu(Anhui Medical University), Yizheng Tu(The University of Texas MD Anderson Cancer Center), W. Fraser Symmans(The University of Texas MD Anderson Cancer Center), Aaron McCoy(The University of Texas MD Anderson Cancer Center), Sahil Seth(The University of Texas MD Anderson Cancer Center)
Cited by 316
Related Papers
The Immune Landscape of Cancer
|Immunity|2018|6.2k
Palbociclib and Letrozole in Advanced Breast Cancer
|New England Journal of Medicine|2016|2.9k
Measurement of Residual Breast Cancer Burden to Predict Survival After Neoadjuvant Chemotherapy
|Journal of Clinical Oncology|2007|1.6k
Residual breast cancers after conventional therapy display mesenchymal as well as tumor-initiating features
|Proceedings of the National Academy of Sciences|2009|1.4k